Keros Therapeutics (NASDAQ:KROS) Trading Down 2.7% After Analyst Downgrade

Keros Therapeutics, Inc. (NASDAQ:KROS) fell 2.7% during trading on Tuesday after Truist Financial lowered their price target on the stock from $100.00 to $43.00. Truist Financial currently has a buy rating on the stock. Keros Therapeutics traded as low as $16.63 and last traded at $16.65. 211,223 shares traded hands during mid-day trading, a decline of 57% from the average session volume of 487,966 shares. The stock had previously closed at $17.12.

A number of other analysts have also commented on KROS. TD Cowen lowered shares of Keros Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Cantor Fitzgerald reissued an “overweight” rating on shares of Keros Therapeutics in a research report on Friday, November 22nd. HC Wainwright reduced their price objective on shares of Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating for the company in a research note on Friday, December 13th. Oppenheimer lowered their target price on Keros Therapeutics from $102.00 to $63.00 and set an “outperform” rating on the stock in a research report on Monday, December 16th. Finally, Scotiabank dropped their target price on Keros Therapeutics from $77.00 to $44.00 and set a “sector outperform” rating on the stock in a report on Friday, December 13th. Four equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $75.00.

Hedge Funds Weigh In On Keros Therapeutics

A number of institutional investors have recently bought and sold shares of the business. KBC Group NV lifted its position in shares of Keros Therapeutics by 52.0% in the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after buying an additional 432 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Keros Therapeutics by 26.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after acquiring an additional 280 shares during the period. Values First Advisors Inc. acquired a new stake in Keros Therapeutics during the 3rd quarter valued at $89,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Keros Therapeutics during the second quarter worth $128,000. Finally, LMR Partners LLP acquired a new position in shares of Keros Therapeutics in the third quarter valued at $213,000. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Price Performance

The company’s 50-day moving average price is $53.23 and its two-hundred day moving average price is $51.17. The company has a market capitalization of $676.87 million, a P/E ratio of -3.21 and a beta of 1.20.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company had revenue of $0.39 million for the quarter. During the same period in the previous year, the business earned ($1.33) EPS. The firm’s revenue was up 4750.0% on a year-over-year basis. On average, analysts anticipate that Keros Therapeutics, Inc. will post -5.26 earnings per share for the current fiscal year.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.